A case of fulminant subacute sclerosing panencephalitis presenting with acute myoclonic-astatic epilepsy

Fabio Magurano1, Gian Luca Marella2, Antonella Marchi1

  • 1Laboratorio Nazionale di Riferimento per il Morbillo e la Rosolia, Dipartimento di Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy.

Insights

Subacute sclerosing panencephalitis (SSPE) is a rare, fatal neurologic sequela of measles. This report details a fulminant Italian case of SSPE, resulting in death within months.

Area of Science:

  • Neurology
  • Virology
  • Pediatrics

Background:

  • Measles infection can lead to rare but severe neurologic sequelae, including subacute sclerosing panencephalitis (SSPE).
  • SSPE arises from persistent defective measles virus particles in brain cells, years after initial infection.
  • Typical SSPE presentation involves intellectual decline, behavioral changes, and myoclonic jerks, often leading to death within two years.

Observation:

  • This report describes an unusual case of fulminant SSPE in an Italian patient.
  • The patient experienced rapid disease progression, leading to death within months of symptom onset.

Findings:

  • The case highlights the potential for extremely rapid and fatal progression of SSPE.
  • This presentation deviates from the typical slower, progressive course of the disease.

Implications:

  • This case underscores the importance of measles vaccination to prevent SSPE.
  • Further research may be needed to understand the factors contributing to fulminant SSPE presentations.
  • Clinicians should be aware of the possibility of rapid SSPE progression, even in vaccinated populations if immunity wanes.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.9K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
867
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K